Citigroup
ANAB icon

Citigroup’s AnaptysBio ANAB Stock Holding History

Citigroup’s Portfolio ANAB Stock Details ANAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.07M Sell
73,406
-47
-0.1% -$2.53K ﹤0.01% 2123
2025
Q4 		$3.56M Buy
73,453
+2,919
+4% +$114K ﹤0.01% 2260
2025
Q3 		$2.16M Sell
70,534
-975,954
-93% -$22.4M ﹤0.01% 2614
2025
Q2 		$23.2M Sell
1,046,488
-24,759
-2% -$518K 0.01% 893
2025
Q1 		$19.9M Buy
1,071,247
+1,017,470
+1,892% +$17M 0.01% 974
2024
Q4 		$712K Buy
53,777
+38,376
+249% +$930K ﹤0.01% 3587
2024
Q3 		$516K Buy
15,401
+4,838
+46% +$165K ﹤0.01% 3706
2024
Q2 		$265K Sell
10,563
-68,480
-87% -$1.59M ﹤0.01% 3749
2024
Q1 		$1.78M Buy
79,043
+75,423
+2,084% +$1.79M ﹤0.01% 2525
2023
Q4 		$77.5K Sell
3,620
-31,508
-90% -$543K ﹤0.01% 4310
2023
Q3 		$631K Buy
35,128
+1,334
+4% +$25.5K ﹤0.01% 2886
2023
Q2 		$687K Sell
33,794
-30,928
-48% -$627K ﹤0.01% 3133
2023
Q1 		$1.41M Buy
64,722
+30,477
+89% +$741K ﹤0.01% 2287
2022
Q4 		$1.06M Sell
34,245
-36,877
-52% -$1.04M ﹤0.01% 2564
2022
Q3 		$1.81M Buy
71,122
+29,779
+72% +$698K ﹤0.01% 2219
2022
Q2 		$839K Buy
41,343
+31,746
+331% +$703K ﹤0.01% 2806
2022
Q1 		$237K Sell
9,597
-28,427
-75% -$860K ﹤0.01% 3987
2021
Q4 		$1.32M Buy
38,024
+15,474
+69% +$491K ﹤0.01% 2972
2021
Q3 		$612K Sell
22,550
-54,028
-71% -$1.37M ﹤0.01% 3475
2021
Q2 		$1.99M Sell
76,578
-37,574
-33% -$901K ﹤0.01% 2677
2021
Q1 		$2.46M Buy
114,152
+107,066
+1,511% +$2.7M ﹤0.01% 2366
2020
Q4 		$152K Buy
7,086
+3,881
+121% +$94.2K ﹤0.01% 5194
2020
Q3 		$47K Sell
3,205
-26,459
-89% -$477K ﹤0.01% 5634
2020
Q2 		$662K Sell
29,664
-11,918
-29% -$218K ﹤0.01% 3971
2020
Q1 		$587K Sell
41,582
-9,450
-19% -$143K ﹤0.01% 3723
2019
Q4 		$829K Buy
51,032
+16,415
+47% +$388K ﹤0.01% 3955
2019
Q3 		$1.21M Buy
34,617
+4,524
+15% +$215K ﹤0.01% 3421
2019
Q2 		$1.7M Buy
30,093
+28,841
+2,304% +$2.08M ﹤0.01% 3051
2019
Q1 		$91K Sell
1,252
-112,080
-99% -$7.74M ﹤0.01% 5834
2018
Q4 		$7.23M Buy
113,332
+71,150
+169% +$5.29M 0.01% 1515
2018
Q3 		$4.21M Sell
42,182
-8,941
-17% -$742K ﹤0.01% 2024
2018
Q2 		$3.63M Sell
51,123
-37,382
-42% -$3.14M ﹤0.01% 2138
2018
Q1 		$9.21M Sell
88,505
-45,013
-34% -$5.07M 0.01% 1295
2017
Q4 		$13.4M Buy
133,518
+10,879
+9% +$801K 0.01% 1081
2017
Q3 		$4.29M Buy
122,639
+120,787
+6,522% +$3.26M ﹤0.01% 1912
2017
Q2 		$44K Buy
1,852
+1,712
+1,223% +$43K ﹤0.01% 5871
2017
Q1 		$4K Buy
+140
New +$3.26K ﹤0.01% 6843

Other funds holding ANAB

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Citigroup's ANAB Position: Q1 2026 in Review

Citigroup reduced its AnaptysBio (ANAB) stake by 0.06% in Q1 2026, selling an estimated $2.53K and leaving 73,406 shares worth $4.07M. The position accounts for ﹤0.01% of the portfolio, ranked #2123.

Citigroup first reported a position in ANAB in Q1 2017 and has held it in 37 quarters since. The position peaked at $23.2M in Q2 2025. 207 funds tracked by Wall St. Rank hold ANAB as of Q1 2026.

  • Citigroup held 73,406 shares of AnaptysBio worth $4.07M as of Q1 2026.
  • Citigroup sold 47 AnaptysBio shares in Q1 2026, an estimated $2.53K.
  • AnaptysBio made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #2123 holding.
  • Citigroup first reported a position in AnaptysBio in Q1 2017 and has held it in 37 quarters since.
  • Citigroup's AnaptysBio position peaked at $23.2M in Q2 2025.
  • 207 funds tracked by Wall St. Rank held AnaptysBio as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.